Physostigmine salicylate is used as an ophthalmic agent for the treatment of primary angle-closure glaucoma and occasionally for primary open-angle glaucoma; it acts as a reversible acetylcholinesterase (AChE) inhibitor that crosses the blood-brain barrier to enhance central cholinergic neurotransmission, reverses memory deficits in Alzheimer's disease transgenic mice, and serves as an antidote for anticholinergic poisoning.